Do GLP-1RA and SGLT2i Reduce Cardiovascular Mortality in African American Patients with Type 2 Diabetes? A Meta-analysis

被引：0
|
作者：
Mishriky, Basem M.
Powell, James R.
Wittwer, Jennifer A.
Chu, Jennifer X.
Sewell, Kerry
Wu, Qiang
Cummings, Doyle M.
机构：
来源：
DIABETES | 2019年 / 68卷
关键词：
D O I：
10.2337/db19-242-OR
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
242-OR
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Uptake and Predictors of SGLT2i in Patients with Type 2 Diabetes and Cardiovascular Disease
    Ozaki, Aya F.
    Ko, Dennis T.
    Chong, Alice
    Fang, Jiming
    Austin, Peter
    Stukel, Therese
    Booth, Gillian
    Tu, Karen
    Udell, Jacob A.
    Atzema, Clare
    Naimark, David
    Jackevicius, Cynthia A.
    CIRCULATION, 2021, 144
  • [42] The Cardiovascular Benefits and Infections Risk of SGLT2i versus Metformin in Type 2 Diabetes: A Systemic Review and Meta-Analysis
    Xu, Chunmei
    He, Liping
    Zhang, Jing
    Xu, Lusi
    Dong, Jianjun
    Liao, Lin
    METABOLITES, 2022, 12 (10)
  • [43] SGLT2i Increased the Fasting Glucagon Level in Patients with Diabetes: A Meta-analysis
    Zhu, Xingyun
    Lin, Chu
    Li, Li
    Hu, Suiyuan
    Cai, Xiaoling
    Ji, Linong
    DIABETES, 2021, 70
  • [44] Genetic Mimics of GLP-1Ra and SGLT2i Therapy, Heart Failure and Chronic Kidney Disease Outcomes
    Remala, Subbaramireddy
    Liang, Liming
    Shah, Amil
    Buckley, Leo
    CIRCULATION, 2024, 150
  • [45] Efficacy and safety of traditional Chinese medicine and SGLT2i, GLP-1RA, and ACEI/ARB in the management of diabetic kidney disease: A systematic review and network meta-analysis
    Liu, Jiarong
    Xu, Jixiong
    RHEUMATOLOGY & AUTOIMMUNITY, 2025,
  • [46] The Risk of Major CV Events after Initiation of SGLT2i, GLP-1RA, DPP-4i, or SUs in Patients with Type 2 Diabetes and Low-toModerate CV Risk
    Patorno, Elisabetta
    Tesfaye, Helen
    Alix, Caroline
    Dicesare, Elyse C.
    Cromer, Sara Jane
    Everett, Brendan M.
    Glynn, Robert
    Wexler, Deborah J.
    Paik, Julie M.
    DIABETES, 2024, 73
  • [47] The Risk of Heart Failure Hospitalization after Initiation of SGLT2i, GLP-1RA, DPP-4i, or SUs in Patients with Type 2 Diabetes and Low-to-Moderate CV Risk
    Tesfaye, Helen
    Paik, Julie M.
    Alix, Caroline
    Cromer, Sara Jane
    Everett, Brendan M.
    Glynn, Robert
    Wexler, Deborah J.
    Patorno, Elisabetta
    DIABETES, 2024, 73
  • [48] Combined treatment with SGLT2i and GLP1ra compared with SGLT2i or GLP1ra alone improves survival: a Real-World Registry
    Garcia Vega, D.
    Cinza-Sanjurjo, S.
    Eiras, S.
    Gonzalez-Juanatey, J. R.
    EUROPEAN JOURNAL OF HEART FAILURE, 2024, 26 : 591 - 591
  • [49] Association of formulary restrictions and initiation of an SGLT2i or GLP1-RA among Medicare beneficiaries with type 2 diabetes
    Luo, Jing
    Gabriel, Nico
    Korytkowski, Mary
    Hernandez, Inmaculada
    Gellad, Walid F.
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2022, 187
  • [50] Risk of Cardiovascular Outcomes in Patients With Type 2 Diabetes After Addition of SGLT2 Inhibitors Versus Sulfonylureas to Baseline GLP-1RA Therapy
    Dave, Chintan V.
    Kim, Seoyoung C.
    Goldfine, Allison B.
    Glynn, Robert J.
    Tong, Angela
    Patorno, Elisabetta
    CIRCULATION, 2021, 143 (08) : 770 - 779
12345